非小细胞肺癌脑转移患者的免疫治疗：临床挑战与未来方向
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.
作者信息
Pathak Ranjan, Amini Arya, Hill Addie, Massarelli Erminia, Salgia Ravi
机构信息
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
Department of Radiation Oncology, City of Hope, Duarte, CA 91010, USA.
出版信息
Cancers (Basel). 2021 Jul 7;13(14):3407. doi: 10.3390/cancers13143407.
Abstract
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with non-small cell lung cancers. Existing treatment paradigms for brain metastases in lung cancer patients leave patients with adverse neurocognitive function, poor quality of life, and dismal prognosis, thus highlighting the need to develop more effective systemic therapies. Although data are limited, emerging knowledge suggests promising activity and safety of immune checkpoint inhibitors in brain metastases in non-small cell lung cancer patients. This review aims to summarize the current data, highlight the challenges of incorporating immune checkpoint inhibitors in treating these patients, and identify areas for future research.
摘要
免疫检查点抑制剂彻底改变了非小细胞肺癌患者的治疗格局。肺癌患者脑转移的现有治疗模式使患者出现不良神经认知功能、生活质量差和预后不佳的情况，因此凸显了开发更有效全身治疗方法的必要性。尽管数据有限，但新出现的知识表明免疫检查点抑制剂在非小细胞肺癌患者脑转移中的活性和安全性颇具前景。本综述旨在总结当前数据，强调将免疫检查点抑制剂纳入这些患者治疗中的挑战，并确定未来研究的领域。
相似文献
1
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.非小细胞肺癌脑转移患者的免疫治疗：临床挑战与未来方向
Cancers (Basel). 2021 Jul 7;13(14):3407. doi: 10.3390/cancers13143407.
2
Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.抗 PD-(L)1 免疫疗法治疗非小细胞肺癌脑转移：机制、进展和挑战。
Cancer Lett. 2021 Apr 1;502:166-179. doi: 10.1016/j.canlet.2020.12.043. Epub 2021 Jan 13.
3
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
4
Research advances in immune checkpoint drugs for non-small cell lung cancer.免疫检查点抑制剂治疗非小细胞肺癌的研究进展。
J Drug Target. 2023 Aug;31(7):700-713. doi: 10.1080/1061186X.2023.2235098. Epub 2023 Jul 14.
5
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.免疫检查点抑制剂治疗伴脑转移的非小细胞肺癌的研究进展。
Lung Cancer. 2023 Oct;184:107322. doi: 10.1016/j.lungcan.2023.107322. Epub 2023 Aug 10.
6
[Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].[免疫治疗机制进展及PD-1/PD-L1检查点抑制剂用于非小细胞肺癌脑转移的当前证据]
Zhongguo Fei Ai Za Zhi. 2020 Nov 20;23(11):976-982. doi: 10.3779/j.issn.1009-3419.2020.102.31. Epub 2020 Aug 10.
7
Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.传统治疗方法与免疫疗法在肺癌和间皮瘤中的作用。
Cancer Treat Res. 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5.
8
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.免疫疗法治疗表皮生长因子受体（EGFR）突变型肺癌：当前挑战与新策略
Front Oncol. 2021 May 25;11:635007. doi: 10.3389/fonc.2021.635007. eCollection 2021.
9
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.非小细胞肺癌脑转移患者的免疫治疗。了解脑肿瘤微环境并剖析临床免疫检查点阻断治疗的结果。
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
10
Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.PD-1/L1 抑制剂在非小细胞肺癌脑转移中的疗效：来自七个随机对照试验的汇总分析。
Future Oncol. 2022 Jan;18(3):403-412. doi: 10.2217/fon-2021-0795. Epub 2021 Nov 17.
引用本文的文献
1
Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies.非小细胞肺癌脑转移患者的免疫检查点抑制：新出现的机制和个性化临床策略
Int J Mol Sci. 2025 Sep 4;26(17):8624. doi: 10.3390/ijms26178624.
2
The role of nursing in enhancing quality of life for lung cancer patients receiving targeted and immunotherapy: Challenges, opportunities, and future directions.护理在提高接受靶向治疗和免疫治疗的肺癌患者生活质量中的作用：挑战、机遇与未来方向。
Hum Vaccin Immunother. 2025 Dec;21(1):2506302. doi: 10.1080/21645515.2025.2506302. Epub 2025 May 20.
3
Lack of Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer in Real Life, with the Emergence of Immunotherapy.现实生活中广泛期小细胞肺癌缺乏预防性颅脑照射以及免疫治疗的出现
Cancers (Basel). 2024 Dec 9;16(23):4122. doi: 10.3390/cancers16234122.
4
Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis.IV期非小细胞肺癌脑转移患者对免疫治疗的完全且持久缓解。
Oncoscience. 2024 Oct 8;11:92-98. doi: 10.18632/oncoscience.609. eCollection 2024.
5
Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.脑转移瘤切除术后的体能状态改善和全身治疗进展：一项非小细胞肺癌患者回顾性单中心队列研究。
BMC Cancer. 2024 Aug 21;24(1):1030. doi: 10.1186/s12885-024-12798-2.
6
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.新型免疫检查点抑制剂联合治疗与化疗作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项网络荟萃分析。
Thorac Cancer. 2024 May;15(15):1246-1262. doi: 10.1111/1759-7714.15310. Epub 2024 Apr 16.
7
Management of brain metastases in non-small cell lung cancer without actionable driver mutations-the need to dive deeper in the right 'pool'.无可靶向驱动突变的非小细胞肺癌脑转移的管理——需要在合适的“群体”中进行更深入的研究。
Transl Lung Cancer Res. 2023 Oct 31;12(10):1966-1971. doi: 10.21037/tlcr-23-571. Epub 2023 Oct 25.
8
Stereotactic Radiosurgery Results in Non-Small-Cell Lung Cancer Patients with Brain Metastases in the Era of Modern Systemic Treatment Agents.现代全身治疗药物时代非小细胞肺癌脑转移患者的立体定向放射外科治疗结果
Thorac Res Pract. 2023 Sep;24(5):270-275. doi: 10.5152/ThoracResPract.2023.23025.
9
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.脑转移对广泛期小细胞肺癌一线度伐利尤单抗联合铂类-依托泊苷治疗模式和结局的影响（CASPIAN研究）：简要报告
JTO Clin Res Rep. 2022 Apr 26;3(6):100330. doi: 10.1016/j.jtocrr.2022.100330. eCollection 2022 Jun.
10
KRT8 Serves as a Novel Biomarker for LUAD and Promotes Metastasis and EMT NF-κB Signaling.角蛋白8作为肺腺癌的一种新型生物标志物，促进转移和上皮-间质转化及核因子κB信号传导。
Front Oncol. 2022 May 19;12:875146. doi: 10.3389/fonc.2022.875146. eCollection 2022.
本文引用的文献
1
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.帕博利珠单抗单药治疗程序性死亡配体1阳性且伴有脑转移的非小细胞肺癌患者的疗效：KEYNOTE-001、010、024和042的汇总分析
JTO Clin Res Rep. 2021 Jul 1;2(8):100205. doi: 10.1016/j.jtocrr.2021.100205. eCollection 2021 Aug.
2
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.帕博利珠单抗联合铂类化疗治疗 NSCLC 合并稳定脑转移患者的疗效：KEYNOTE-021、-189 和 -407 的汇总分析。
J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12.
3
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.帕博利珠单抗治疗脑转移的非小细胞肺癌患者的结局。
Clin Lung Cancer. 2021 Jan;22(1):58-66.e3. doi: 10.1016/j.cllc.2020.10.017. Epub 2020 Nov 11.
4
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.系统抗 PD-1 免疫疗法导致脑脊液中的 T 细胞发生 PD-1 阻断。
JAMA Oncol. 2020 Dec 1;6(12):1947-1951. doi: 10.1001/jamaoncol.2020.4508.
5
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.帕博利珠单抗治疗非小细胞肺癌伴脑转移患者的效果：来自一项非随机、开放标签、2 期临床试验的长期结果和生物标志物分析。
Lancet Oncol. 2020 May;21(5):655-663. doi: 10.1016/S1470-2045(20)30111-X. Epub 2020 Apr 3.
6
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.免疫检查点抑制剂治疗患者中使用类固醇与生存的关联：一项系统评价和荟萃分析。
Cancers (Basel). 2020 Feb 27;12(3):546. doi: 10.3390/cancers12030546.
7
Current multidisciplinary management of brain metastases.脑转移瘤的多学科综合治疗现状。
Cancer. 2020 Apr 1;126(7):1390-1406. doi: 10.1002/cncr.32714. Epub 2020 Jan 23.
8
Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review.脑转移瘤患者立体定向放射手术后的健康相关生活质量：系统、叙事综述。
Support Care Cancer. 2020 Feb;28(2):473-484. doi: 10.1007/s00520-019-05136-x. Epub 2019 Dec 2.
9
Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis.放疗联合免疫治疗脑转移瘤：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2019 Dec;144:102830. doi: 10.1016/j.critrevonc.2019.102830. Epub 2019 Nov 1.
10
Complications associated with immunotherapy for brain metastases.脑转移瘤免疫治疗相关并发症。
Curr Opin Neurol. 2019 Dec;32(6):907-916. doi: 10.1097/WCO.0000000000000756.
Zotero 插件